Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2013

01-12-2013 | Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Interventions to Reduce Alcohol Use among HIV-Infected Individuals: A Review and Critique of the Literature

Authors: Jennifer L. Brown, Kelly S. DeMartini, Jessica M. Sales, Andrea L. Swartzendruber, Ralph J. DiClemente

Published in: Current HIV/AIDS Reports | Issue 4/2013

Login to get access

Abstract

Alcohol use disorders are common among HIV-infected individuals and are associated with adverse physiological complications and increased engagement in other health risk behaviors. This paper provides a review and critique of interventions to reduce alcohol use among HIV-infected individuals, including a: (a) synthesis of core intervention components and trial designs; (b) summary of intervention efficacy to reduce alcohol use outcomes; and (c) methodological critique and guidance for future research. We reviewed 14 behavioral interventions that reported on alcohol use outcomes among HIV-infected individuals. Findings were mixed for intervention efficacy to reduce alcohol frequency and quantity. There was limited evidence that interventions reduced binge drinking frequency or alcohol abuse or dependence symptoms. Despite the prevalence of disordered alcohol use among HIV-infected individuals, there is lack of efficacious intervention approaches. Efficacious intervention approaches to reduce alcohol use among HIV-infected individuals are urgently needed.
Literature
1.
CDC: Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. HIV Surveillance Supplemental Report. 2012, 17.
2.
WHO: Global HIV/AIDS Response: Epidemic update and health sector progress towards universal access. 2011.
3.
CDC: HIV Surveillance Report, 2011. 2013, 23.
4.
Klinkenberg WD, Sacks S. Mental disorders and drug abuse in persons living with HIV/AIDS. AIDS Care. 2004;16:S22–42.PubMedCrossRef
5.
Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr. 2006;42:298–306.PubMedCrossRef
6.
Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63:179–86.PubMed
7.
Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43:411–7.PubMedCrossRef
8.
Michel L, Carrieri MP, Fugon L, et al. Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention. AIDS Care. 2010;22:1136–45.PubMedCrossRef
9.
Sullivan LE, Goulet JL, Justice AC, Fiellin DA. Alcohol consumption and depressive symptoms over time: a longitudinal study of patients with and without HIV infection. Drug Alcohol Depend. 2011;117:158–63.PubMedCrossRef
10.
Persidsky Y, Ho W, Ramirez SH, et al. HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun. 2011;25:S61–70.PubMedCrossRef
11.
Weber E, Morgan EE, Iudicello JE, et al. Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol. 2013;19:65–74.PubMedCrossRef
12.
Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse. 2006;41:1395–463.PubMedCrossRef
13.
Barve S, Kapoor R, Moghe A, et al. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Res Health. 2010;33:229–36.PubMed
14.
Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. Alcohol Res Health. 2010;33:280–7.PubMed
15.
Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805.PubMedCrossRef
16.
17.
Ferrari LF, Levine JD. Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms. Eur J Neurosci. 2010;32:811–8.PubMedCrossRef
18.
Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose–response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005;29:1190–7.PubMedCrossRef
19.
Grierson J, Koelmeyer RL, Smith A, Pitts M. Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians. HIV Med. 2011;12:562–9.PubMedCrossRef
20.
Carrieri MP, Spire B, Lert F, Michel L. Time to combine intervention with prevention in countries where HIV is also driven by hazardous drinking. Addiction. 2013;108:221–2.PubMedCrossRef
21.
Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52:180–202.PubMedCrossRef
22.
Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res. 2004;28:572–7.PubMedCrossRef
23.
Balfour L, Kowal J, Silverman A, et al. A randomized controlled psycho-education intervention trial: improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care. 2006;18:830–8.PubMedCrossRef
24.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMedCrossRef
25.
Clavel F, Hance AJ. HIV drug resistance. New Engl J Med. 2004;350:1023–35.PubMed
26.
Simoni JM, Montgomery A, Martin E, et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119:e1371–83.PubMedCrossRef
27.
Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11:299–307.PubMedCrossRef
28.
Yuan Y, L’Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7:156–62.PubMedCrossRef
29.
• Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112:178–93. This paper provides a review of the effects of alcohol use disorders among HIV-infected individuals on antiretroviral medication adherence, health care utilization, and biological endpoints.PubMedCrossRef
30.
Samet JH, Cheng DM, Libman H, et al. Alcohol consumption and HIV disease progression. JAIDS: J Acquir Immune Defic Syndr. 2007;46:194–9.PubMedCrossRef
31.
Cunningham WE, Sohler NL, Tobias C, et al. Health services utilization for people with HIV infection: comparison of a population targeted for outreach with the U.S. population in care. Med Care. 2006;44:1038–47.PubMedCrossRef
32.
Kim TW, Kertesz SG, Horton NJ, Tibbetts N, Samet JH. Episodic homelessness and health care utilization in a prospective cohort of HIV-infected persons with alcohol problems. BMC Health Serv Res. 2006;6:19.PubMedCrossRef
33.
Gordon AJ, McGinnis KA, Conigliaro J, et al. Associations between alcohol use and homelessness with healthcare utilization among human immunodeficiency virus-infected veterans. Med Care. 2006;44:S37–43.PubMedCrossRef
34.
Theall KP, Amedee A, Clark RA, Dumestre J, Kissinger P. Alcohol consumption and HIV-1 vaginal RNA shedding among women. J Stud Alcohol Drugs. 2008;69:454–8.PubMed
35.
Homans J, Christensen S, Stiller T, et al. Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr. 2012;60:99–110.PubMedCrossRef
36.
Stein M, Herman DS, Trisvan E, et al. Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons. Alcohol Clin Exp Res. 2005;29:837–43.PubMedCrossRef
37.
Hasse B, Ledergerber B, Hirschel B, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2010;51:1314–22.PubMedCrossRef
38.
Dirks H, Esser S, Borgmann R, et al. Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med. 2012;13:533–40.PubMed
39.
Theall KP, Clark RA, Powell A, Smith H, Kissinger P. Alcohol consumption, ART usage and high-risk sex among women infected with HIV. AIDS Behav. 2007;11:205–15.PubMedCrossRef
40.
Saggurti N, Raj A, Mahapatra B, et al. Prevalence and correlates of non-disclosure of HIV serostatus to sex partners among HIV-infected female sex workers and HIV-infected male clients of female sex workers in India. AIDS Behav. 2013;17:399–406.PubMedCrossRef
41.
•• Samet JH, Walley AY. Interventions targeting HIV-infected risky drinkers: drops in the bottle. Alcohol Res Health. 2010;33:267–79. This paper conducted a review of studies with HIV-infected individuals with past or current unhealthy alcohol use and studies with samples comprised of 10% or more currently using alcohol.PubMed
42.
Aharonovich E, Hatzenbuehler ML, Johnston B, et al. A low-cost, sustainable intervention for drinking reduction in the HIV primary care setting. AIDS Care. 2006;18:561–8.PubMedCrossRef
43.
Murphy DA, Chen X, Naar-King S, Parsons JT. Alcohol and marijuana use outcomes in the healthy choices motivational interviewing intervention for HIV-positive youth. AIDS Patient Care STDs. 2012;26:95–100.PubMedCrossRef
44.
Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46:443–50.PubMedCrossRef
45.
Velasquez MM, von Sternberg K, Johnson DH, et al. Reducing sexual risk behaviors and alcohol use among HIV-positive men who have sex with men: a randomized clinical trial. J Consult Clin Psychol. 2009;77:657–67.PubMedCrossRef
46.
Gilbert P, Ciccarone D, Gansky SA, et al. Interactive “Video Doctor” counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. Plos One. 2008;3:e1988.PubMedCrossRef
47.
Naar-King S, Wright K, Parsons JT, et al. Healthy choices: motivational enhancement therapy for health risk behaviors in HIV-positive youth. AIDS Care. 2006;18:1–11.
48.
Naar-King S, Lam P, Wang B, et al. Brief report: maintenance of effects of motivational enhancement therapy to improve risk behaviors and HIV-related Health in a randomized controlled trial of youth living with HIV. J Pediatr Psychol. 2008;33:441–5.PubMedCrossRef
49.
Samet JH, Horton NJ, Meli S, et al. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther. 2005;10:83–93.PubMed
50.
Meade CS, Drabkin AS, Hansen NB, et al. Reductions in alcohol and cocaine use following a group coping intervention for HIV-positive adults with childhood sexual abuse histories. Addiction. 2010;105:1942–51.PubMedCrossRef
51.
Papas RK, Sidle JE, Gakinya BN, et al. Treatment outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya. Addiction. 2011;106:2156–66.PubMedCrossRef
52.
Jones DL, Weiss SM, Chitalu N, et al. Sexual risk intervention in multiethnic drug and alcohol users. Am J Infect Dis. 2007;3:169–76.PubMedCrossRef
53.
Wong FL, Rotheram-Borus MJ, Lightfoot M, et al. Effects of behavioral intervention on substance use among people living with HIV: the Healthy Living Project randomized controlled study. Addiction. 2008;103:1206–14.PubMedCrossRef
54.
Rotheram-Borus MJ, Lee MB, Murphy DA, et al. Efficacy of a preventive intervention for youths living with HIV. Am J Public Health. 2001;91:400–5.PubMedCrossRef
55.
Rotheram-Borus MJ, Swendeman D, Comulada WS, et al. Prevention for substance-using HIV-positive young people: telephone and in-person delivery. J Acquir Immune Defic Syndr. 2004;37 Suppl 2:S68–77.PubMedCrossRef
56.
Rotheram-Borus MJ, Desmond K, Comulada WS, Arnold EM, Johnson M. Reducing risky sexual behavior and substance use among currently and formerly homeless adults living with HIV. Am J Public Health. 2009;99:1100–7.PubMedCrossRef
57.
Sorensen JL, Dilley J, London J, et al. Case management for substance abusers with HIV/AIDS: a randomized clinical trial. Am J Drug Alcohol Abuse. 2003;29:133–50.PubMedCrossRef
58.
Schroder KE, Carey MP, Vanable PA. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med. 2003;26:104–23.PubMedCrossRef
59.
Catania JA, Gibson DR, Chitwood DD, Coates TJ. Methodological problems in AIDS behavioral research: influences on measurement error and participation bias in studies of sexual behavior. Psychol Bull. 1990;108:339–62.PubMedCrossRef
60.
Weinhardt LS, Forsyth AD, Carey MP, Jaworski BC, Durant LE. Reliability and validity of self-report measures of HIV-related sexual behavior: progress since 1990 and recommendations for research and practice. Arch Sex Behav. 1998;27:155–80.PubMedCrossRef
61.
Midanik LT. Validity of self-reported alcohol use: a literature review and assessment. Br J Addict. 1988;83:1019–30.PubMedCrossRef
62.
Fiellin DA, McGinnis KA, Maisto SA, Justice AC, Bryant K. Measuring alcohol consumption using Timeline Followback in non-treatment-seeking medical clinic patients with and without HIV infection: 7-, 14-, or 30-day recall. J Stud Alcohol Drugs. 2013;74:500–4.PubMed
63.
Shiffman S. Ecological momentary assessment (EMA) in studies of substance use. Psychol Assess. 2009;21:486–97.PubMedCrossRef
64.
Jones J, Jones M, Plate C, et al. Liquid chromatography-tandem mass spectrometry assay to detect ethyl glucuronide in human fingernail: comparison to hair and gender differences. Am J Analyt Chem. 2012;3:83–91.CrossRef
65.
Junghanns K, Graf I, Pflüger J, et al. Urinary ethyl glucuronide (EtG) and ethyl sulphate (EtS) assessment: valuable tools to improve verification of abstention in alcohol-dependent patients during in-patient treatment and at follow-ups. Addiction. 2009;104:921–6.PubMedCrossRef
66.
Bower JE, Kemeny ME, Fawzy FI. Group interventions for individuals with serious medical illness. In: Chesney M, Antoni MH, editors. Innovative approaches to health psychology: prevention and treatment lessons from AIDS. Washington D.C: American Psychological Association; 2002. p. 197–218.CrossRef
67.
Kalichman SC, Catz SL. Stressors in HIV infection. In: Nott KH, Vedhara K, editors. Psychosocial and biomedical interactions in HIV infection. Amsterdam Netherlands: Harwood Academic; 2000. p. 31–60.
68.
Riper H, van Straten A, Keuken M, et al. Curbing problem drinking with personalized-feedback interventions: a meta-analysis. Am J Prevent Med. 2009;36:247–55.CrossRef
69.
McGinn LK, Sanderson WC. What allows cognitive behavioral therapy to be brief: overview, efficacy, and crucial factors facilitating brief treatment. Clin Psychol Sci Pract. 2001;8:23–37.CrossRef
70.
Atkins DC, Bedics JD, McGlinchey JB, Beauchaine TP. Assessing clinical significance: does it matter which method we use? J of Consult and Clin Psychol. 2005;73:982–89.
71.
Jacobson NS, Roberts LJ, Berns SB, McGlinchey JB. Methods for defining and determining clinical significance of treatment effects: description, application, alternatives. J of Consult and Clin Psychol. 1999;67:300–7.
72.
Kazdin AE. The meanings and measurement of clinical significance. J of Consult and Clin Psychol. 1999;67:332–9.
73.
Kendall PC, Marrs-Garcia A, Nath SR, Sheldrick RC. Normative comparisons for the evaluation of clinical significance. J of Consult and Clin Psychol. 1999;67:285–99.
Metadata
Title
Interventions to Reduce Alcohol Use among HIV-Infected Individuals: A Review and Critique of the Literature
Authors
Jennifer L. Brown
Kelly S. DeMartini
Jessica M. Sales
Andrea L. Swartzendruber
Ralph J. DiClemente
Publication date
01-12-2013
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 4/2013
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-013-0174-8

Other articles of this Issue 4/2013

Current HIV/AIDS Reports 4/2013 Go to the issue

HIV/HCV Coinfection (N Terrault, Section Editor)

Treatment of Genotype 2 and Genotype 3 Hepatitis C Virus (HCV) Infection in Human Immunodeficiency Virus Positive Patients

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Validity of Cognitive Screens for HIV-Associated Neurocognitive Disorder: A Systematic Review and an Informed Screen Selection Guide

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Case Management Interventions for HIV-Infected Individuals

HIV/HCV Coinfection (N Terrault, Section Editor)

After the Cure: Management of HCV After Achievement of SVR

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Treatment Considerations for HIV-Infected Individuals with Severe Mental Illness

Behavioral Aspects of HIV Management (RJ DiClemente and JL Brown, Section Editors)

Seroadaptation among Men Who Have Sex with Men: Emerging Research Themes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits